Congenital amegakaryocytic thrombocytopenia

Congenital amegakaryocytic thrombocytopenia
Synonyms	CAMT
Pronounce	N/A
Specialty	N/A
Symptoms	Thrombocytopenia, bleeding, bruising
Complications	Bone marrow failure, leukemia
Onset	Neonatal
Duration	Lifelong
Types	N/A
Causes	Genetic mutation in the MPL gene
Risks	Family history
Diagnosis	Blood test, bone marrow biopsy, genetic testing
Differential diagnosis	Thrombocytopenia absent radius syndrome, Fanconi anemia
Prevention	N/A
Treatment	Hematopoietic stem cell transplantation, platelet transfusion
Medication	Thrombopoietin receptor agonists
Prognosis	N/A
Frequency	Rare
Deaths	N/A

A rare inherited bone marrow failure syndrome

Congenital amegakaryocytic thrombocytopenia (CAT) is a rare genetic disorder characterized by a significant reduction in the number of platelets due to a failure of the bone marrow to produce megakaryocytes, the precursor cells to platelets. This condition is present at birth and is classified as a type of bone marrow failure syndrome.

Pathophysiology

Congenital amegakaryocytic thrombocytopenia is primarily caused by mutations in the MPL gene, which encodes the thrombopoietin receptor. Thrombopoietin is a crucial growth factor for the development of megakaryocytes. Mutations in the MPL gene lead to a lack of response to thrombopoietin, resulting in the absence or severe reduction of megakaryocytes in the bone marrow and consequently, thrombocytopenia.

Clinical Presentation

Patients with CAT typically present with symptoms related to low platelet counts, such as:

• Petechiae
• Ecchymosis
• Epistaxis
• Gingival bleeding
• Increased risk of intracranial hemorrhage

The condition is usually diagnosed in infancy or early childhood when these symptoms become apparent.

Diagnosis

The diagnosis of congenital amegakaryocytic thrombocytopenia involves:

• Complete blood count (CBC) showing isolated thrombocytopenia
• Bone marrow biopsy revealing a lack of megakaryocytes
• Genetic testing to identify mutations in the MPL gene

Management

Management of CAT focuses on supportive care and may include:

• Platelet transfusions to manage bleeding episodes
• Hematopoietic stem cell transplantation (HSCT) as a potential curative treatment

Prognosis

The prognosis for individuals with congenital amegakaryocytic thrombocytopenia varies. Without treatment, patients are at risk for severe bleeding complications. Hematopoietic stem cell transplantation can offer a cure, but the success of the procedure depends on various factors, including the availability of a suitable donor and the patient's overall health.

Related pages

• Thrombocytopenia
• Bone marrow failure
• Hematopoietic stem cell transplantation